Refine Biology Raises Series C Financing, with CEC Capital Serving as Exclusive Financial Advisor

Refine Biology recently announced the closing of a several hundred million RMB Series C financing round. The round was led by Xingxiang Asset Management Group, with participation from Royal Power XMXYG Fund as a co-investor. Proceeds from this financing will be primarily allocated to advancing the company’s commercial expansion and the implementation of new production capacity, accelerating R&D innovation, technological iteration and market development across its dual platforms for human health and animal health.

CEC Capital acted as the exclusive financial advisor to Refine Biology for this transaction.

As a nationally leading intelligent manufacturing platform and solution provider for biosynthesis based on natural ingredients, Refine Biology was founded in 2007. Adhering to the pursuit of "purer nature", "more efficient nature" and "earth-friendly nature", the company is committed to becoming a trusted innovation partner in the global health industry. It strives to drive the sustainable development of natural raw materials, support the "carbon neutrality" strategy, redefine the concept of natural products, empower holistic health, and deliver integrated solutions that combine taste, functionality, nutrition, appearance and cost-effectiveness for enterprises in the food, beverage and nutraceutical sectors.